- Home
- HMST vs MOLN Comparison
HMST vs MOLN Comparison
Compare HMST & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- MOLN
- Stock Information
- Founded
- HMST 1921
- MOLN 2004
- Country
- HMST United States
- MOLN Switzerland
- Employees
- HMST 819
- MOLN N/A
- Industry
- HMST Major Banks
- MOLN
- Sector
- HMST Finance
- MOLN
- Exchange
- HMST Nasdaq
- MOLN Nasdaq
- Market Cap
- HMST 194.6M
- MOLN 192.4M
- IPO Year
- HMST 2012
- MOLN 2021
- Fundamental
- Price
- HMST $10.32
- MOLN $5.04
- Analyst Decision
- HMST Buy
- MOLN
- Analyst Count
- HMST 2
- MOLN 0
- Target Price
- HMST $14.75
- MOLN N/A
- AVG Volume (30 Days)
- HMST 176.5K
- MOLN 5.7K
- Earning Date
- HMST 01-27-2025
- MOLN 03-13-2025
- Dividend Yield
- HMST N/A
- MOLN N/A
- EPS Growth
- HMST N/A
- MOLN N/A
- EPS
- HMST N/A
- MOLN N/A
- Revenue
- HMST $75,702,000.00
- MOLN $7,105,397.00
- Revenue This Year
- HMST N/A
- MOLN N/A
- Revenue Next Year
- HMST $9.32
- MOLN $29.41
- P/E Ratio
- HMST N/A
- MOLN N/A
- Revenue Growth
- HMST N/A
- MOLN N/A
- 52 Week Low
- HMST $8.09
- MOLN $3.32
- 52 Week High
- HMST $16.10
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- HMST 47.32
- MOLN 41.97
- Support Level
- HMST $9.61
- MOLN $5.22
- Resistance Level
- HMST $10.58
- MOLN $5.35
- Average True Range (ATR)
- HMST 0.56
- MOLN 0.12
- MACD
- HMST 0.02
- MOLN -0.03
- Stochastic Oscillator
- HMST 53.42
- MOLN 0.00
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.